Novel Program of Using Village Health Workers in Early Detection and Awareness of Head and Neck Cancers: Audit of a Community Screening Program
The objective of this programme was to indoctrinate the most vulnerable and the least tended upon; the basics of head and neck cancers via the medium of their own kins. Voluntary village health workers were educated and trained to pick up the early signs of head and neck cancers. Oral self examination was taught to them and they went to peripheral villages to screen the population. They would refer suspicious cases to tertiary healthcare centre. The population was enlightened upon the basics of preventable measures, treatment options and rehabilitation facilities for head and neck cancer patients. Knowledge, attitude and practice analysis was done in the population which showed widespread disbelief and false practices. A population of 26,10,432 was surveyed in 1862 villages of which 10,522 (1.1%) individuals successfully quit the habit. The minimally educated workers referred 3309 suspicious individuals to higher centre of which 1890 (57.11%) tested positive for cancer. A lot of resource is put in research and development of rapid diagnosis and complete cure; however such a minimally costing program may help the most in primordial, primary and secondary level of prevention. Such programs should be advocated on the global platform on lines of Breast Self Examination.
CONCLUSIONS: Polymorphic variant XRCC1 HNSCC patients treated with CCRT have significantly increased acute radiation morbidities and may have a trend toward better PFS in comparison with the wild variant. PMID: 29893275 [PubMed - in process]
Authors: Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD Abstract The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for o...
Squamous cell carcinoma of the head and neck (SCCHN) includes neoplasms in the oral cavity, pharynx, and larynx, and accounts for 90% of all head and neck cancers [1 –3]. Patients with recurrent/metastatic (R/M) SCCHN who progress within 6 months after platinum-based therapy have poor long-term prognosis and limited treatment options, with a median overall survival (OS) of ≤6 months [4,5]. In 2016, nivolumab was approved in the United States for the trea tment of this patient population, with European approval following in 2017 [6,7].
Head and neck cancer encompasses the cancer of the oral cavity, paranasal sinuses, pharynx, and larynx [1,2]. Head and Neck cancer, which develops at the lips, tongue, salivary glands, gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations , is the sixth most common cancer in the world . The GLOBOCAN 2012 report indicated an estimated 300,400 new cases and 145,400 deaths due to oral cancer, with the highest rates being found in Melanesia and South-Central and Eastern Asia [5,6].
Authors: Ekizoglu S, Ulutin T, Guliyev J, Buyru N Abstract Head and neck squamous cell carcinomas (HNSCC) are a diverse group of tumor types, including neoplasia of the paranasal sinuses, oral cavity, trachea, pharynx and larynx. Laryngeal cancer is the most common type of HNSCC. The proline-rich 4 (PRR4) protein is synthesized in the acinar cells of human lacrimal glands. Previous studies have demonstrated that PRR4 may function as an antimicrobial protein protecting the ocular surface and the oral cavity. In order to determine differentially expressed genes (DEGs) in laryngeal tumors, a GeneFishing Assay was perf...
ConclusionThis is the first described case of grade 4 immune mucositis and esophagitis associated with pembrolizumab. Because the use of pembrolizumab is increasing in oncology, pharmacists and physicians should be aware of this rare manifestation.
Head and neck cancers are cancers of the upper airway and/or digestive tract found in the oral cavity, laryngeal, pharyngeal, oropharyngeal, and hypo-pharyngeal tissues. Head and neck cancers make up 3% of cancers diagnosed each year [1,2]. Head and neck cancer incidence has declined from 25 cases per 100,000 at risk in the 1990s to 15 cases per 100,000 at risk in the present day . While the decrease in head and neck cancer incidence may be due to a drop in tobacco use [4,5], the mortality associated with these cancers has not changed significantly in the last twenty years .
This study aimed to assess the c urrent HNC caseload in a tertiary OMFS unit.
Head and neck squamous cell carcinoma (HNSCC) arises from a number of distinct locations in the upper aerodigestive tract, including the oral cavity, pharynx and larynx . Whilst the treatment of local disease has improved over the last few decades, locoregionally advanced disease has remained a challenge, requiring a multimodal approach of surgery and chemo/radiation therapy [2,3]. Despite intensive efforts, the global 5-year survival of HNSCC remains poor (40 –50%), although in Australia this is now in excess of 60% [4,5].
There were an estimated 61,760 incident cases of head and neck cancer (oral cavity, pharynx, oral cavity, and larynx) in the United States in 2016, accounting for about 3.7% of all new cancer cases . Among oral cavity and pharynx cancer, oral cavity cancer rates are decreasing mostly due to decreases in smoking and alcohol use [2,3]. However, cancers of the base of tongue, tonsil, and oropharynx (oropharyngeal cancer) are increasing because of increases in human papillomavirus (HPV) infection.